BindingDB logo
myBDB logout

56 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28017532 140 Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kd inhibitors.EBI AstraZeneca
26652969 15 Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety.EBI Xi'an Jiaotong University
28109945 25 Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.EBI Hangzhou Xixi Hospital
27923617 70 Novel pyrazolo[1,5-a]pyridines with improved aqueous solubility as p110a-selective PI3 kinase inhibitors.EBI University of Auckland
27816515 143 Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.EBI Merck& Co.
28105286 65 Discovery of a Potent, Selective, and Orally Available PI3Kd Inhibitor for the Treatment of Inflammatory Diseases.EBI Rhône-Poulenc Rorer
27479483 61 6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors.EBI CSIR-Indian Institute of Integrative Medicine
27644332 59 Class II Phosphoinositide 3-Kinases as Novel Drug Targets.EBI Curtin University
27660692 70 Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)- Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate.EBI Infinity Pharmaceuticals, Inc.
27186676 186 Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.EBI West China Hospital of Sichuan University
27043133 16 A Prospective Virtual Screening Study: Enriching Hit Rates and Designing Focus Libraries To Find Inhibitors of PI3Kd and PI3K.EBI Janssen Research& Development
27189888 11 Optimization of the phenylurea moiety in a phosphoinositide 3-kinase (PI3K) inhibitor to improve water solubility and the PK profile by introducing a solubilizing group and ortho substituents.EBI Chugai Pharmaceutical Co., Ltd
26980109 42 2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kd Selective Inhibitors.EBI Gilead Sciences, Inc.
26321603 8 Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity.EBI Xi'an Jiaotong University
23644197 51 Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).EBI University of Auckland
23291120 2 Synthesis and biological evaluation of novel coumarin-pyrazoline hybrids endowed with phenylsulfonyl moiety as antitumor agents.EBI Cairo University
22520259 65 Identification of ETP-46321, a potent and orally bioavailable PI3Ka,d inhibitor.EBI Spanish National Cancer Research Centre (CNIO)
22897589 100 Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511.EBI Amgen Inc.
23040731 4 Viridin analogs derived from steroidal building blocks.EBI University of Connecticut
23063566 70 Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3Ka inhibitors.EBI Universit£ de Nantes
18077363 314 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.EBI University of Oxford
22325943 71 Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.EBI Spanish National Cancer Research Centre (CNIO). C/Melchor Fern£ndez Almagro 3
21621413 24 Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability.EBI Dana Farber Cancer Institute
21322566 61 Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.EBI Dana Farber Cancer Institute
20860370 83 Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.EBI Dana Farber Cancer Institute
17562705 6 Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one.EBI Stony Brook University
16464575 7 Synthesis of fluorescent derivatives of wortmannin and demethoxyviridin as probes for phosphatidylinositol 3-kinase.EBI State University of New York-ESF
11206452 14 3-Deoxy-3-substituted-D-myo-inositol imidazolyl ether lipid phosphates and carbonate as inhibitors of the phosphatidylinositol 3-kinase pathway and cancer cell growth.EBI Georgetown University Medical Center
27082499 10 Discovery of a Highly Selective STK16 Kinase Inhibitor.BDB Chinese Academy of Sciences
19848404 44 Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.BDB Wyeth Research
19645448 48 ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin: Design and Synthesis of Highly Potent and Selective PyrazolopyrimidinesBDB Wyeth Research
19209891 34 New Insights into the Design of Inhibitors of Human S-Adenosylmethionine Decarboxylase: Studies of Adenine C(8) Substitution in Structural Analogues of S-Adenosylmethionine (dagger).BDB Cornell University
19228017 52 Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold.BDB Genentech, Inc.
18817367 28 Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.BDB Abbott Laboratories
17685602 33 Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.BDB TargeGen Inc.
17172449 20 Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.BDB TargeGen Inc.
18754654 19 The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .BDB Piramed Pharma
14722321 9 A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties.BDB Johnson & Johnson Pharmaceutical
18269228 93 Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy.BDB Wyeth Research
11520201 10 X-Ray crystal structures of Candida albicans dihydrofolate reductase: high resolution ternary complexes in which the dihydronicotinamide moiety of NADPH is displaced by an inhibitor.BDB GSK
17574423 44 Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.BDB Pfizer
11090628 5 Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine.BDB MRC
8879560 22 Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA--II. Modification of pyrrolidine ring at P1' proline.BDB Sankyo Co. Ltd.
8893827 17 Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.BDB Upjohn